Heart Failure With Reduced Ejection Fraction (HFrEF)
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Heart Failure With Reduced Ejection Fraction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Heart Failure With Reduced Ejection Fraction (HFrEF): Overview
Heart failure is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ventricular filling or ejection of blood or both. HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodeling. Assessment for heart failure begins with obtaining a medical history and physical examination. Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thresholds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measured by echocardiography. Treatment strategies include the use of diuretics to relieve symptoms and application of an expanding armamentarium of disease-modifying drug and device therapies. Unless there are specific contraindications, patients with HFrEF should be treated with a ?-blocker and one of an angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, with addition of a mineralocorticoid receptor antagonist in patients with persistent symptoms. Ivabradine and hydralazine/isosorbide dinitrate also have a role in the care of certain patients with HFrEF. More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF.
'Heart Failure With Reduced Ejection Fraction - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure With Reduced Ejection Fraction pipeline landscape is provided which includes the disease overview and Heart Failure With Reduced Ejection Fraction treatment guidelines. The assessment part of the report embraces, in depth Heart Failure With Reduced Ejection Fraction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure With Reduced Ejection Fraction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Heart Failure With Reduced Ejection Fraction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure With Reduced Ejection Fraction Emerging Drugs
By targeting AGT, which lies furthest upstream in the RAAS pathway, IONIS-AGT-LRx has the potential to achieve a more complete blockade of the RAAS axis compared to ACE inhibitors and ARBs. Furthermore, the selective inhibition of AGT in the liver may provide a better safety profile by avoiding the kidney side effects seen with the current RAAS inhibitors, which is especially important for patients with chronic kidney dysfunction.
Further product details are provided in the report.
Heart Failure With Reduced Ejection Fraction: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure With Reduced Ejection Fraction drugs segregated based on following parameters that define the scope of the report, such as:
Heart Failure With Reduced Ejection Fraction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure With Reduced Ejection Fraction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure With Reduced Ejection Fraction drugs.
Heart Failure With Reduced Ejection Fraction Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Heart Failure With Reduced Ejection Fraction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Heart Failure With Reduced Ejection Fraction (HFrEF): Overview
Heart failure is a clinical syndrome characterized by dyspnea or exertional limitation due to impairment of ventricular filling or ejection of blood or both. HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodeling. Assessment for heart failure begins with obtaining a medical history and physical examination. Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thresholds and identification of left ventricular systolic dysfunction with LVEF of 40% or less as measured by echocardiography. Treatment strategies include the use of diuretics to relieve symptoms and application of an expanding armamentarium of disease-modifying drug and device therapies. Unless there are specific contraindications, patients with HFrEF should be treated with a ?-blocker and one of an angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, with addition of a mineralocorticoid receptor antagonist in patients with persistent symptoms. Ivabradine and hydralazine/isosorbide dinitrate also have a role in the care of certain patients with HFrEF. More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hospitalization in high-risk patients with HFrEF.
'Heart Failure With Reduced Ejection Fraction - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure With Reduced Ejection Fraction pipeline landscape is provided which includes the disease overview and Heart Failure With Reduced Ejection Fraction treatment guidelines. The assessment part of the report embraces, in depth Heart Failure With Reduced Ejection Fraction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure With Reduced Ejection Fraction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure With Reduced Ejection Fraction R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure With Reduced Ejection Fraction.
This segment of the Heart Failure With Reduced Ejection Fraction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure With Reduced Ejection Fraction Emerging Drugs
- IONIS-AGT-LRx: Ionis Pharmaceuticals
By targeting AGT, which lies furthest upstream in the RAAS pathway, IONIS-AGT-LRx has the potential to achieve a more complete blockade of the RAAS axis compared to ACE inhibitors and ARBs. Furthermore, the selective inhibition of AGT in the liver may provide a better safety profile by avoiding the kidney side effects seen with the current RAAS inhibitors, which is especially important for patients with chronic kidney dysfunction.
- Omecamtiv mecarbil: Cytokinetics
Further product details are provided in the report.
Heart Failure With Reduced Ejection Fraction: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure With Reduced Ejection Fraction drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart Failure With Reduced Ejection Fraction
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Heart Failure With Reduced Ejection Fraction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure With Reduced Ejection Fraction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure With Reduced Ejection Fraction drugs.
Heart Failure With Reduced Ejection Fraction Report Insights
- Heart Failure With Reduced Ejection Fraction Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart Failure With Reduced Ejection Fraction drugs?
- How many Heart Failure With Reduced Ejection Fraction drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure With Reduced Ejection Fraction?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure With Reduced Ejection Fraction therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart Failure With Reduced Ejection Fraction and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ionis Pharmaceuticals
- Cytokinetics
- Salubris Biotherapeutics Inc
- MYK-491
- Stealth BioTherapeutics Inc.
- PhaseBio Pharmaceuticals Inc.
- AstraZeneca
- Sardocor Corp.
- Berlin Cures GmbH
- Innolife Co., Ltd.
- Bayer
- Zensun Sci. & Tech. Co., Ltd.
- Olatec Therapeutics LLC
- Intra-Cellular Therapies, Inc.
- Asklepios Biopharmaceutical, Inc.
- IONIS-AGT-LRx
- Omecamtiv mecarbil
- JK07
- MYK-491
- Elamipretide
- PB1046
- AZD3427
- SRD-001
- BC 007
- INL1
- BAY 1753011
- Recombinant human Neuregulin
- Dapansutrile
- ITI-214
- NAN-101
Introduction
Executive Summary
Heart Failure With Reduced Ejection Fraction: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Heart Failure With Reduced Ejection Fraction – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Omecamtiv mecarbil: Cytokinetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
PB1046: PhaseBio Pharmaceuticals Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
AZD3427: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Heart Failure With Reduced Ejection Fraction Key Companies
Heart Failure With Reduced Ejection Fraction Key Products
Heart Failure With Reduced Ejection Fraction- Unmet Needs
Heart Failure With Reduced Ejection Fraction- Market Drivers and Barriers
Heart Failure With Reduced Ejection Fraction- Future Perspectives and Conclusion
Heart Failure With Reduced Ejection Fraction Analyst Views
Heart Failure With Reduced Ejection Fraction Key Companies
Appendix
Executive Summary
Heart Failure With Reduced Ejection Fraction: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Heart Failure With Reduced Ejection Fraction – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Omecamtiv mecarbil: Cytokinetics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
PB1046: PhaseBio Pharmaceuticals Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
AZD3427: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Heart Failure With Reduced Ejection Fraction Key Companies
Heart Failure With Reduced Ejection Fraction Key Products
Heart Failure With Reduced Ejection Fraction- Unmet Needs
Heart Failure With Reduced Ejection Fraction- Market Drivers and Barriers
Heart Failure With Reduced Ejection Fraction- Future Perspectives and Conclusion
Heart Failure With Reduced Ejection Fraction Analyst Views
Heart Failure With Reduced Ejection Fraction Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Heart Failure With Reduced Ejection Fraction
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Heart Failure With Reduced Ejection Fraction
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Heart Failure With Reduced Ejection Fraction
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Heart Failure With Reduced Ejection Fraction
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
